Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next
New York, Jan 14, 2026, 11:40 AM EST — Regular session Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning. (U.S. Food and Drug Administration) The label change is significant because it addresses a major safety concern that’s been dogging weight-loss drugs, even as demand remains robust and politicians and insurers press on prices. For Lilly, obesity remains the key driver in the stock, and anything that cuts “headline risk” usually gets